[1]
|
Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Riazi, K., Azhari, H., Charette, J.H., Underwood, F.E., King, J.A., Afshar, E.E., et al. (2022) The Prevalence and Incidence of NAFLD Worldwide: A Systematic Review and Meta-Analysis. The Lancet Gastroenterology & Hepatology, 7, 851-861. https://doi.org/10.1016/s2468-1253(22)00165-0
|
[3]
|
Quek, J., Chan, K.E., Wong, Z.Y., Tan, C., Tan, B., Lim, W.H., et al. (2023) Global Prevalence of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis in the Overweight and Obese Population: A Systematic Review and Meta-analysis. The Lancet Gastroenterology & Hepatology, 8, 20-30. https://doi.org/10.1016/s2468-1253(22)00317-x
|
[4]
|
Younossi, Z.M., Golabi, P., de Avila, L., Paik, J.M., Srishord, M., Fukui, N., et al. (2019) The Global Epidemiology of NAFLD and NASH in Patients with Type 2 Diabetes: A Systematic Review and Meta-analysis. Journal of Hepatology, 71, 793-801. https://doi.org/10.1016/j.jhep.2019.06.021
|
[5]
|
Huang, D.Q., El-Serag, H.B. and Loomba, R. (2020) Global Epidemiology of NAFLD-Related HCC: Trends, Predictions, Risk Factors and Prevention. Nature Reviews Gastroenterology & Hepatology, 18, 223-238. https://doi.org/10.1038/s41575-020-00381-6
|
[6]
|
Adams, L.A., Anstee, Q.M., Tilg, H. and Targher, G. (2017) Non-Alcoholic Fatty Liver Disease and Its Relationship with Cardiovascular Disease and Other Extrahepatic Diseases. Gut, 66, 1138-1153. https://doi.org/10.1136/gutjnl-2017-313884
|
[7]
|
Eslam, M., Newsome, P.N., Sarin, S.K., Anstee, Q.M., Targher, G., Romero-Gomez, M., et al. (2020) A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement. Journal of Hepatology, 73, 202-209. https://doi.org/10.1016/j.jhep.2020.03.039
|
[8]
|
Xue, R. and Fan, J.G. (2020) Brief Introduction of an International Expert Consensus Statement: A New Definition of Metabolic Associated Fatty Liver Disease. Journal of Clinical Hepatology, 36, 1224-1227. https://doi.org/10.3969/j.issn.1001-5256.2020.06.007
|
[9]
|
Mittal, S., El-Serag, H.B., Sada, Y.H., Kanwal, F., Duan, Z., Temple, S., et al. (2016) Hepatocellular Carcinoma in the Absence of Cirrhosis in United States Veterans Is Associated with Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 14, 124-131.e1. https://doi.org/10.1016/j.cgh.2015.07.019
|
[10]
|
Stine, J.G., Wentworth, B.J., Zimmet, A., Rinella, M.E., Loomba, R., Caldwell, S.H., et al. (2018) Systematic Review with Meta-Analysis: Risk of Hepatocellular Carcinoma in Non-Alcoholic Steatohepatitis without Cirrhosis Compared to Other Liver Diseases. Alimentary Pharmacology & Therapeutics, 48, 696-703. https://doi.org/10.1111/apt.14937
|
[11]
|
Weinberg, E.M., Trinh, H.N., Firpi, R.J., Bhamidimarri, K.R., Klein, S., Durlam, J., et al. (2021) Lean Americans with Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases. Clinical Gastroenterology and Hepatology, 19, 996-1008.e6. https://doi.org/10.1016/j.cgh.2020.06.066
|
[12]
|
Estes, C., Razavi, H., Loomba, R., Younossi, Z. and Sanyal, A.J. (2017) Modeling the Epidemic of Nonalcoholic Fatty Liver Disease Demonstrates an Exponential Increase in Burden of Disease. Hepatology, 67, 123-133. https://doi.org/10.1002/hep.29466
|
[13]
|
Kanwal, F., Kramer, J.R., Li, L., Dai, J., Natarajan, Y., Yu, X., et al. (2020) Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology, 71, 808-819. https://doi.org/10.1002/hep.31014
|
[14]
|
Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., et al. (2015) Weight Loss through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. Gastroenterology, 149, 367-378.e5. https://doi.org/10.1053/j.gastro.2015.04.005
|
[15]
|
(2016) EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-alcoholic Fatty Liver Disease. Journal of Hepatology, 64, 1388-1402.
|
[16]
|
Rinella, M.E., Neuschwander-Tetri, B.A., Siddiqui, M.S., Abdelmalek, M.F., Caldwell, S., Barb, D., et al. (2023) AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease. Hepatology, 77, 1797-1835. https://doi.org/10.1097/hep.0000000000000323
|
[17]
|
Ryan, M.C., Itsiopoulos, C., Thodis, T., Ward, G., Trost, N., Hofferberth, S., et al. (2013) The Mediterranean Diet Improves Hepatic Steatosis and Insulin Sensitivity in Individuals with Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 59, 138-143. https://doi.org/10.1016/j.jhep.2013.02.012
|
[18]
|
Luu, H.N., Neelakantan, N., Geng, T., Wang, R., Goh, G.B., Clemente, J.C., et al. (2020) Quality Diet Indexes and Risk of Hepatocellular Carcinoma: Findings from the Singapore Chinese Health Study. International Journal of Cancer, 148, 2102-2114. https://doi.org/10.1002/ijc.33367
|
[19]
|
Jensen, T., Abdelmalek, M.F., Sullivan, S., Nadeau, K.J., Green, M., Roncal, C., et al. (2018) Fructose and Sugar: A Major Mediator of Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 68, 1063-1075. https://doi.org/10.1016/j.jhep.2018.01.019
|
[20]
|
van der Windt, D.J., Sud, V., Zhang, H., Tsung, A. and Huang, H. (2018) The Effects of Physical Exercise on Fatty Liver Disease. Gene Expression, 18, 89-101. https://doi.org/10.3727/105221617x15124844266408
|
[21]
|
Saran, U., Guarino, M., Rodríguez, S., Simillion, C., Montani, M., Foti, M., et al. (2018) Anti-Tumoral Effects of Exercise on Hepatocellular Carcinoma Growth. Hepatology Communications, 2, 607-620. https://doi.org/10.1002/hep4.1159
|
[22]
|
Younossi, Z.M., Corey, K.E. and Lim, J.K. (2021) AGA Clinical Practice Update on Lifestyle Modification Using Diet and Exercise to Achieve Weight Loss in the Management of Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology, 160, 912-918. https://doi.org/10.1053/j.gastro.2020.11.051
|
[23]
|
Lassailly, G., Caiazzo, R., Ntandja-Wandji, L., Gnemmi, V., Baud, G., Verkindt, H., et al. (2020) Bariatric Surgery Provides Long-Term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology, 159, 1290-1301.e5. https://doi.org/10.1053/j.gastro.2020.06.006
|
[24]
|
Lee, Y., Doumouras, A.G., Yu, J., Brar, K., Banfield, L., Gmora, S., et al. (2019) Complete Resolution of Nonalcoholic Fatty Liver Disease after Bariatric Surgery: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 17, 1040-1060.e11. https://doi.org/10.1016/j.cgh.2018.10.017
|
[25]
|
Kwok, R., Choi, K.C., Wong, G.L., Zhang, Y., Chan, H.L., Luk, A.O., et al. (2015) Screening Diabetic Patients for Non-Alcoholic Fatty Liver Disease with Controlled Attenuation Parameter and Liver Stiffness Measurements: A Prospective Cohort Study. Gut, 65, 1359-1368. https://doi.org/10.1136/gutjnl-2015-309265
|
[26]
|
Vetrano, E., Rinaldi, L., Mormone, A., Giorgione, C., Galiero, R., Caturano, A., et al. (2023) Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-Viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies. Biomedicines, 11, Article 468. https://doi.org/10.3390/biomedicines11020468
|
[27]
|
Chen, J., Song, S., Li, X., Bian, D. and Wu, X. (2022) Association of Metabolic Traits with Occurrence of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Longitudinal Cohort Studies. Saudi Journal of Gastroenterology, 28, 92-100. https://doi.org/10.4103/sjg.sjg_260_21
|
[28]
|
Kramer, J.R., Natarajan, Y., Dai, J., Yu, X., Li, L., El-Serag, H.B., et al. (2021) Effect of Diabetes Medications and Glycemic Control on Risk of Hepatocellular Cancer in Patients with Nonalcoholic Fatty Liver Disease. Hepatology, 75, 1420-1428. https://doi.org/10.1002/hep.32244
|
[29]
|
Francque, S.M., Bedossa, P., Ratziu, V., Anstee, Q.M., Bugianesi, E., Sanyal, A.J., et al. (2021) A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in Nash. New England Journal of Medicine, 385, 1547-1558. https://doi.org/10.1056/nejmoa2036205
|
[30]
|
Newsome, P.N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., et al. (2021) A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. New England Journal of Medicine, 384, 1113-1124. https://doi.org/10.1056/nejmoa2028395
|
[31]
|
Armstrong, M.J., Gaunt, P., Aithal, G.P., Barton, D., Hull, D., Parker, R., et al. (2016) Liraglutide Safety and Efficacy in Patients with Non-Alcoholic Steatohepatitis (LEAN): A Multicentre, Double-Blind, Randomised, Placebo-Controlled Phase 2 Study. The Lancet, 387, 679-690. https://doi.org/10.1016/s0140-6736(15)00803-x
|
[32]
|
Kapodistria, K., Tsilibary, E., Kotsopoulou, E., Moustardas, P. and Kitsiou, P. (2018) Liraglutide, a Human Glucagon-Like Peptide-1 Analogue, Stimulates AKT-Dependent Survival Signalling and Inhibits Pancreatic β-Cell Apoptosis. Journal of Cellular and Molecular Medicine, 22, 2970-2980. https://doi.org/10.1111/jcmm.13259
|
[33]
|
Le Roux, C.W., et al. (2017) 3 Years of Liraglutide versus Placebo for Type 2 Diabetes Risk Reduction and Weight Management in Individuals with Prediabetes: A Randomised, Double-Blind Trial. Lancet, 389, 1399-1409.
|
[34]
|
Gilbert, M.P. and Pratley, R.E. (2020) GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-To-Head Clinical Trials. Frontiers in Endocrinology, 11, Article 178. https://doi.org/10.3389/fendo.2020.00178
|
[35]
|
Latva-Rasku, A., Honka, M., Kullberg, J., Mononen, N., Lehtimäki, T., Saltevo, J., et al. (2019) The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study with 8-Week Treatment in Type 2 Diabetes Patients. Diabetes Care, 42, 931-937. https://doi.org/10.2337/dc18-1569
|
[36]
|
Steven, S., Oelze, M., Hanf, A., Kröller-Schön, S., Kashani, F., Roohani, S., et al. (2017) The SGLT2 Inhibitor Empagliflozin Improves the Primary Diabetic Complications in ZDF Rats. Redox Biology, 13, 370-385. https://doi.org/10.1016/j.redox.2017.06.009
|
[37]
|
Shiba, K., Tsuchiya, K., Komiya, C., Miyachi, Y., Mori, K., Shimazu, N., et al. (2018) Canagliflozin, an SGLT2 Inhibitor, Attenuates the Development of Hepatocellular Carcinoma in a Mouse Model of Human Nash. Scientific Reports, 8, Article No. 2362. https://doi.org/10.1038/s41598-018-19658-7
|
[38]
|
He, K., Li, J., Xi, W., Ge, J., Sun, J. and Jing, Z. (2022) Dapagliflozin for Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Diabetes Research and Clinical Practice, 185, Article ID: 109791. https://doi.org/10.1016/j.diabres.2022.109791
|
[39]
|
Heidenreich, P.A., Bozkurt, B., Aguilar, D., Allen, L.A., Byun, J.J., Colvin, M.M., et al. (2022) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology, 79, 1757-1780. https://doi.org/10.1016/j.jacc.2021.12.011
|
[40]
|
Li, Y., Liu, L., Wang, B., Wang, J. and Chen, D. (2012) Metformin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Biomedical Reports, 1, 57-64. https://doi.org/10.3892/br.2012.18
|
[41]
|
Vilar-Gomez, E., Vuppalanchi, R., Desai, A.P., Gawrieh, S., Ghabril, M., Saxena, R., et al. (2019) Long-Term Metformin Use May Improve Clinical Outcomes in Diabetic Patients with Non-Alcoholic Steatohepatitis and Bridging Fibrosis or Compensated Cirrhosis. Alimentary Pharmacology & Therapeutics, 50, 317-328. https://doi.org/10.1111/apt.15331
|
[42]
|
Tseng, C. (2018) Metformin and Risk of Hepatocellular Carcinoma in Patients with Type 2 Diabetes. Liver International, 38, 2018-2027. https://doi.org/10.1111/liv.13872
|
[43]
|
de Oliveira, S., Houseright, R.A., Graves, A.L., Golenberg, N., Korte, B.G., Miskolci, V., et al. (2019) Metformin Modulates Innate Immune-Mediated Inflammation and Early Progression of NAFLD-Associated Hepatocellular Carcinoma in Zebrafish. Journal of Hepatology, 70, 710-721. https://doi.org/10.1016/j.jhep.2018.11.034
|
[44]
|
Kasper, P., Martin, A., Lang, S., Kütting, F., Goeser, T., Demir, M., et al. (2020) NAFLD and Cardiovascular Diseases: A Clinical Review. Clinical Research in Cardiology, 110, 921-937. https://doi.org/10.1007/s00392-020-01709-7
|
[45]
|
Duell, P.B., Welty, F.K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., et al. (2022) Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology, 42, e168-e185. https://doi.org/10.1161/atv.0000000000000153
|
[46]
|
Targher, G., Byrne, C.D., Lonardo, A., Zoppini, G. and Barbui, C. (2016) Non-Alcoholic Fatty Liver Disease and Risk of Incident Cardiovascular Disease: A Meta-Analysis. Journal of Hepatology, 65, 589-600. https://doi.org/10.1016/j.jhep.2016.05.013
|
[47]
|
Wong, C.R. and Lim, J.K. (2018) The Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease Outcomes. Clinical Liver Disease, 12, 39-44. https://doi.org/10.1002/cld.721
|
[48]
|
Ayada, I., van Kleef, L.A., Zhang, H., Liu, K., Li, P., Abozaid, Y.J., et al. (2023) Dissecting the Multifaceted Impact of Statin Use on Fatty Liver Disease: A Multidimensional Study. eBioMedicine, 87, Article ID: 104392. https://doi.org/10.1016/j.ebiom.2022.104392
|
[49]
|
Sharma, R., Simon, T.G., Hagström, H., Lochhead, P., Roelstraete, B., Söderling, J., et al. (2024) Statins Are Associated with a Decreased Risk of Severe Liver Disease in Individuals with Noncirrhotic Chronic Liver Disease. Clinical Gastroenterology and Hepatology, 22, 749-759.e19. https://doi.org/10.1016/j.cgh.2023.04.017
|
[50]
|
Abdallah, M., Brown, L., Provenza, J., Tariq, R., Gowda, S. and Singal, A.K. (2022) Safety and Efficacy of Dyslipidemia Treatment in NAFLD Patients: A Meta-Analysis of Randomized Controlled Trials. Annals of Hepatology, 27, Article ID: 100738. https://doi.org/10.1016/j.aohep.2022.100738
|
[51]
|
Zou, B., Odden, M.C. and Nguyen, M.H. (2023) Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients with Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 21, 435-444.e6. https://doi.org/10.1016/j.cgh.2022.01.057
|
[52]
|
Singh, S., Singh, P.P., Singh, A.G., Murad, M.H. and Sanchez, W. (2013) Statins Are Associated with a Reduced Risk of Hepatocellular Cancer: A Systematic Review and Meta-Analysis. Gastroenterology, 144, 323-332. https://doi.org/10.1053/j.gastro.2012.10.005
|
[53]
|
Li, X., Liu, L. and Hu, Y. (2020) Statin Use and the Prognosis of Patients with Hepatocellular Carcinoma: A Meta-Analysis. Bioscience Reports, 40, BSR20200232. https://doi.org/10.1042/bsr20200232
|
[54]
|
Simon, T.G., Henson, J., Osganian, S., Masia, R., Chan, A.T., Chung, R.T., et al. (2019) Daily Aspirin Use Associated with Reduced Risk for Fibrosis Progression in Patients with Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 17, 2776-2784.e4. https://doi.org/10.1016/j.cgh.2019.04.061
|
[55]
|
Simon, T.G., Ma, Y., Ludvigsson, J.F., Chong, D.Q., Giovannucci, E.L., Fuchs, C.S., et al. (2018) Association between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncology, 4, 1683-1690. https://doi.org/10.1001/jamaoncol.2018.4154
|
[56]
|
Lee, C., Hsu, C., Yen, T., Wu, T., Yu, M. and Hsieh, S. (2023) Daily Aspirin Reduced the Incidence of Hepatocellular Carcinoma and Overall Mortality in Patients with Cirrhosis. Cancers, 15, Article 2946. https://doi.org/10.3390/cancers15112946
|
[57]
|
Saber, S., Mahmoud, A.A.A., Goda, R., Helal, N.S., El-ahwany, E. and Abdelghany, R.H. (2018) Perindopril, Fosinopril and Losartan Inhibited the Progression of Diethylnitrosamine-Induced Hepatocellular Carcinoma in Mice via the Inactivation of Nuclear Transcription Factor κ-B. Toxicology Letters, 295, 32-40. https://doi.org/10.1016/j.toxlet.2018.05.036
|
[58]
|
Zhang, X., Wong, G.L., Yip, T.C., Tse, Y., Liang, L.Y., Hui, V.W., et al. (2022) Angiotensin-Converting Enzyme Inhibitors Prevent Liver-Related Events in Nonalcoholic Fatty Liver Disease. Hepatology, 76, 469-482. https://doi.org/10.1002/hep.32294
|
[59]
|
Goh, G.B., Pagadala, M.R., Dasarathy, J., Unalp-Arida, A., Sargent, R., Hawkins, C., et al. (2014) Renin-Angiotensin System and Fibrosis in Non-Alcoholic Fatty Liver Disease. Liver International, 35, 979-985. https://doi.org/10.1111/liv.12611
|